Earlier, in October 2009, the division of reproductive and urologic products at FDA has issued a complete response letter for the biologic license application (BLA) for Prolia in the treatment and prevention of postmenopausal osteoporosis.
The letter requested several items, including further information on the design of Amgen’s previously submitted post-marketing surveillance program. The letter did not require additional pre-marketing clinical trials to complete the review of the treatment indication.
The FDA has also requested all updated safety data related to Prolia. Amgen has submitted the requested information for the treatment indication in late January 2010.
Amgen continues to work with the FDA to determine appropriate next steps regarding its indications for Prolia in the prevention of postmenopausal osteoporosis, as well as in the treatment and prevention of bone loss due to hormone ablation in breast and prostate cancer patients.